Recursion Doses First Patient In REC-1245 Cancer Therapy Trial

Recursion is a clinical-stage TechBio company leveraging advanced technology to improve health care radically. The firm has announced that the first patient has been treated in its Phase 1/2 clinical trial of REC-1245. This novel and innovative drug candidate is being developed to treat biomarker-enriched solid tumours and lymphoma.

Dr. McKean, a clinical investigator at START Mountain Region in Salt Lake City, Utah, said in a statement, “The evolution of precision and personalised treatment options for oncology patients provides promising alternatives. We are so pleased to be working with Recursion as a participating site in the DAHLIA trial, and we look forward to advancing the science of cancer treatment.”

Using its AI-driven biological mapping platform, Recursion discovered a novel regulatory role for RBM39 in influencing CDK12 function. The company believes modulating RBM39 may provide therapeutic benefits for specific solid tumours and lymphoma cases identified by biomarkers. Preclinical studies indicate that degrading RBM39 leads to splicing defects, which suppress DNA Damage Response (DDR) pathways and cell cycle checkpoints.

Najat Khan, PhD, Chief R&D Officer and Chief Commercial Officer of Recursion, commented, “Dosing the first patient in the DAHLIA trial marks a pivotal moment for Recursion as we combine the power of our AI-enabled platform with cutting-edge science to pioneer a new class of targeted therapies. REC-1245 represents not only a potential breakthrough for patients with biomarker-enriched cancers but also a testament to our ability to rapidly translate novel insights into clinical programs. This milestone exemplifies our commitment to transforming the future of oncology with precision and speed.”

The DAHLIA trial, an open-label Phase 1/2 study, aims to evaluate REC-1245's safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and objective response rate (ORR). The trial will also determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). REC-1245 has potential as an independent treatment and is combined with other therapies, such as DDR inhibitors, checkpoint inhibitors, or chemotherapy.